益生菌改善骨关节炎患者的功能表现:一个随机的安慰剂控制的临床试验
Asima Karim1,2, Haroon Ahmed Khan3, Firdos Ahmad4,5
1Department of Basic Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates. akarim@sharjah.ac.ae.
European journal of nutrition
|October 9, 2025
概括
多种菌株益生菌显著改善了骨关节炎患者的功能能力,减少疼痛并提高了运动能力. 佐努林的变化表明与肠道透性有联系,需要进一步调查.
科学领域:
- 整形外科和运动医学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 骨关节炎 (OA) 是一种导致严重残疾的退行性关节疾病.
- 目前对OA的治疗方法无法治愈,这凸显了需要新的治疗策略的需要.
- 新兴研究表明,肠道健康在OA等系统性炎症疾病中可能发挥作用.
研究的目的:
- 研究一种特定的多菌株益生菌 (Vivomix 1120 亿) 对改善关节炎患者功能表现的疗效.
- 评估益生菌对OA患者疼痛,关节功能,移动性,炎症和肠道透性的影响.
主要方法:
- 进行了一项为期16周的单中心,双盲,随机,安慰剂对照试验.
- 115名OA患者 (60-75岁) 随机分配每天接受益生菌或安慰剂.
- 测量结果包括疼痛 (VAS),牛津膝盖得分 (OKS),运动范围 (ROM),短物理性能电池 (SPPB),步行速度,手握强度 (HGS),血 zonulin,C反应蛋白 (CRP) 和8-isoprostanes.
主要成果:
- 与安慰剂相比,益生菌补充剂显著降低了血阳素和行走过程中的疼痛.
- 从基线看,益生菌组的OKS,ROM,步行速度,HGS和SPPB得分有显著改善.
- 益生菌还导致了CRP水平的显著降低, zonulin的变化与OKS,SPPB和HGS的改善有很强的相关性.
结论:
- 多种菌株益生菌在增强功能能力和减少骨关节炎患者疼痛方面显示出潜力.
- 观察到的松林水平的变化表明肠道透性和OA症状改善之间可能存在联系.
- 需要进一步的研究来确定益生菌诱导的肠道透性变化和OA的功能结果之间的因果关系.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
637
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
637
Inflammatory Bowel Disease IV: Pharmacological Management
517
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
517
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
488
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
488
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
434
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
434
Drugs for Treatment of Ulcerative Colitis in IBD
456
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
456
Drugs for Treatment of Constipation-Predominant IBS
717
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717

